I’ve been working with Professor Barnes since 2007 and have mainly been working on the Phase 1 clinical candidate HCV vaccine studies that have been carried out in Oxford, looking at their immunogenicity in healthy volunteers and HCV patients.
I have also been involved in the NGS work of various pathogenic viruses, particularly HCV, that has been set up in collaboration with the Welcome Trust Centre for Human Genomics.
In addition to these main roles I have been looking at the immune response to HEV in HEV exposed individuals from Cornwall and Oxford in a collaboration with Dr Harry Dalton.
HCV sequencing and vaccination, all aspects of HEV infection and viral sequencing
PEACHI vaccine study, STOP-HCV viral sequencing and host immune response to HEV infection
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Frater J. et al, (2021), Lancet HIV, 8, e474 - e485
Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV).
McNaughton AL. et al, (2019), Sci Rep, 9
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
Smith D. et al, (2019), Hepatology, 69, 1861 - 1872
Rolling circle amplification and nanopore-based deep sequencing of full-length HBV genomes
Mcnaughton A. et al, (2018), JOURNAL OF HEPATOLOGY, 68, S762 - S762
The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
von Delft A. et al, (2018), Vaccine, 36, 313 - 321